Dianthus Therapeutics, Inc. (DNTH)
(Delayed Data from NSDQ)
$29.06 USD
-0.84 (-2.81%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $28.93 -0.13 (-0.45%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth D Momentum D VGM
Price, Consensus and EPS Surprise
DNTH 29.06 -0.84(-2.81%)
Will DNTH be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for DNTH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DNTH
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates
Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass Estimates
DNTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength?
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
Other News for DNTH
Dianthus Therapeutics Reports Q3 Progress and Financials
A Glimpse Into The Expert Outlook On Dianthus Therapeutics Through 4 Analysts
Dianthus Therapeutics GAAP EPS of -$0.74, revenue of $2.17M
Buy Recommendation for Dianthus Therapeutics: Strong Financial Position and Promising Drug Pipeline
Dianthus reports Q3 EPS (74c), consensus (59c)